Mecapegfilgrastim for peripheral blood stem cell mobilization in patients with lymphoproliferative diseases

Mecapegfilgrastim for peripheral blood stem cell mobilization in patients with hematologic malignancies

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074548

Enrollment

Unknown

Registered

2023-08-09

Start date

2022-09-22

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies

Interventions

Control group:rhG-CSF mobilization

Experimental group:Mecapegfilgrastim mobilization

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ? Age 18-60 years old; ? The diagnosis of lymphoproliferative disease was confirmed by histopathological examination, and the histopathological diagnosis criteria were based on the WHO Classification of Hematopoietic and lymphoid Tissue Tumors, 2016 edition. ? There are clear indications for autologous stem cell transplantation

Exclusion criteria

Exclusion criteria: ? Age 60 years; ? severe cardiopulmonary insufficiency; ? No indication for autologous stem cell transplantation. Any of the above conditions will be excluded.

Design outcomes

Primary

Measure	Time frame
The quantity of CD34+ cell collection;	—

Secondary

Measure	Time frame
The quantity of mononuclear cell collection;	—

Countries

China

Contacts

Public ContactXufang

Department of Hematology, Mianyang Central Hospital

147377807@qq.com+86 137 7813 8821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026